Literature DB >> 3275670

Total sacrectomy and reconstruction for primary tumors. Report of two cases.

J Shikata1, T Yamamuro, Y Kotoura, Y Mikawa, H Iida, S Maetani.   

Abstract

Entities:  

Mesh：

Year:  1988        PMID： 3275670

Source DB:  PubMed          Journal:  J Bone Joint Surg Am        ISSN： 0021-9355            Impact factor:   5.284


× No keyword cloud information.
  7 in total

1.  Surgical classification of different types of en bloc resection for primary malignant sacral tumors.

Authors:  Dasen Li; Wei Guo; Xiaodong Tang; Tao Ji; Yidan Zhang
Journal:  Eur Spine J       Date:  2011-06-29       Impact factor: 3.134

Review 2.  Surgical techniques for spinopelvic reconstruction following total sacrectomy: a systematic review.

Authors:  S Samuel Bederman; Kalpit N Shah; Jeffrey M Hassan; Bang H Hoang; P Douglas Kiester; Nitin N Bhatia
Journal:  Eur Spine J       Date:  2013-10-23       Impact factor: 3.134

3.  The rare case of giant cell tumor occuring in the axial skeleton after 15 years of follow-up: Case report.

Authors:  Ye-Soo Park; Jin Kyu Lee; Seung-Wook Baek; Chan-Kum Park
Journal:  Oncol Lett       Date:  2011-09-02       Impact factor: 2.967

4.  The problem of stabilization after sacrectomy.

Authors:  G Blatter; E G Halter Ward; G Ruflin; B Jeanneret
Journal:  Arch Orthop Trauma Surg       Date:  1994       Impact factor: 3.067

5.  Reconstruction of the pelvic ring after tumour resection.

Authors:  P C Leung
Journal:  Int Orthop       Date:  1992       Impact factor: 3.075

6.  A case study using total en bloc sacrectomy and neuroanastomosis for sacral tumor.

Authors:  Guoquan Zheng; Songhua Xiao; Yonggang Zhang; Xuesong Zhang; Zheng Wang; Yan Wang
Journal:  Eur Spine J       Date:  2014-05-16       Impact factor: 3.134

7.  Imaging appearances and clinical outcome following sacrectomy and ilio-lumbar reconstruction for sacral neoplasia.

Authors:  Marianna Thomas; A M Davies; A J Stirling; R J Grimer; M Grainger; Steven L J James
Journal:  Skeletal Radiol       Date:  2013-11-17       Impact factor: 2.199
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.